Capturing a Comprehensive Picture of Biological Events From Adverse Outcome Pathways in the Drug Exposome

被引:1
|
作者
Wu, Qier [1 ]
Bagdad, Youcef [1 ]
Taboureau, Olivier [2 ]
Audouze, Karine [1 ]
机构
[1] Univ Paris, INSERM U1124, CNRS ERL 3649, Paris, France
[2] Univ Paris, INSERM U 1133, CNRS UMR 8251, Paris, France
关键词
network science; AOP; bipartite network; drug-AOP; AON; NAM; SYSTEMS BIOLOGY; EXPOSURE; ENVIRONMENT; TOXICOLOGY; RESOURCE; NETWORK; MODELS; GENOME;
D O I
10.3389/fpubh.2021.763962
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The chemical part of the exposome, including drugs, may explain the increase of health effects with outcomes such as infertility, allergies, metabolic disorders, which cannot be only explained by the genetic changes. To better understand how drug exposure can impact human health, the concepts of adverse outcome pathways (AOPs) and AOP networks (AONs), which are representations of causally linked events at different biological levels leading to adverse health, could be used for drug safety assessment.Methods: To explore the action of drugs across multiple scales of the biological organization, we investigated the use of a network-based approach in the known AOP space. Considering the drugs and their associations to biological events, such as molecular initiating event and key event, a bipartite network was developed. This bipartite network was projected into a monopartite network capturing the event-event linkages. Nevertheless, such transformation of a bipartite network to a monopartite network had a huge risk of information loss. A way to solve this problem is to quantify the network reduction. We calculated two scoring systems, one measuring the uncertainty and a second one describing the loss of coverage on the developed event-event network to better investigate events from AOPs linked to drugs.Results: This AON analysis allowed us to identify biological events that are highly connected to drugs, such as events involving nuclear receptors (ER, AR, and PXR/SXR). Furthermore, we observed that the number of events involved in a linkage pattern with drugs is a key factor that influences information loss during monopartite network projection. Such scores have the potential to quantify the uncertainty of an event involved in an AON, and could be valuable for the weight of evidence assessment of AOPs. A case study related to infertility, more specifically to "decrease, male agenital distance" is presented.Conclusion: This study highlights that computational approaches based on network science may help to understand the complexity of drug health effects, with the aim to support drug safety assessment.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events
    L. Konttinen
    V. Honkanen
    T. Uotila
    J. Pöllänen
    M. Waahtera
    M. Romu
    K. Puolakka
    M. Vasala
    A. Karjalainen
    R. Luukkainen
    D. C. Nordström
    [J]. Rheumatology International, 2006, 26 : 916 - 922
  • [42] Human Endocrine-Disrupting Effects of Phthalate Esters through Adverse Outcome Pathways: A Comprehensive Mechanism Analysis
    Li, Yunxiang
    Yang, Hao
    He, Wei
    Li, Yu
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [43] The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review
    Duong, Mai H.
    Gnjidic, Danijela
    McLachlan, Andrew J.
    Sakiris, Marissa A.
    Goyal, Parag
    Hilmer, Sarah N.
    [J]. DRUGS & AGING, 2022, 39 (08) : 631 - 643
  • [44] The Prevalence of Adverse Drug Reactions and Adverse Drug Events from Heart Failure Medications in Frail Older Adults: A Systematic Review
    Mai H. Duong
    Danijela Gnjidic
    Andrew J. McLachlan
    Marissa A. Sakiris
    Parag Goyal
    Sarah N. Hilmer
    [J]. Drugs & Aging, 2022, 39 : 631 - 643
  • [45] Prediction of Molecular Initiating Events for Adverse Outcome Pathways Using High-Throughput Identification of Chemical Targets
    Lizano-Fallas, Veronica
    del Amor, Ana Carrasco
    Cristobal, Susana
    [J]. TOXICS, 2023, 11 (02)
  • [46] A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment
    Halappanavar, Sabina
    Ede, James D.
    Mahapatra, Indrani
    Krug, Harald F.
    Kuempel, Eileen D.
    Lynch, Iseult
    Vandebriel, Rob J.
    Shatkin, Jo Anne
    [J]. NANOTOXICOLOGY, 2021, 15 (03) : 289 - 310
  • [47] The Spectrum of Neurological Adverse Events from Immune Checkpoint Blockade: A Comprehensive Review of Literature
    Daher, Ahmad
    Tummala, Sudhakar
    [J]. NEUROLOGY, 2017, 88
  • [48] Parade (Patients at Risk for Adverse Drug Events) model for outcome-driven admission medication reconciliation
    Manz, Boryana
    Julka, Manjula
    Alvarez, Kristin
    Sharma, Varun
    [J]. IMPLEMENTATION SCIENCE, 2017, 13
  • [49] Parade (Patients at Risk for Adverse Drug Events) model for outcome-driven admission medication reconciliation
    Manz, Boryana
    Julka, Manjula
    Alvarez, Kristin
    Sharma, Varun
    [J]. IMPLEMENTATION SCIENCE, 2018, 13
  • [50] Authenticity and credibility aware detection of adverse drug events from social media
    Hoang, Tao
    Liu, Jixue
    Pratt, Nicole
    Zheng, Vincent W.
    Chang, Kevin C.
    Roughead, Elizabeth
    Li, Jiuyong
    [J]. INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2018, 120 : 157 - 171